Cargando…

Neuroblastic Tumours in Children: Outcome from a Referral Centre in India

BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Basant, Yadav, Rajanikant, Upadhyaya, Vijai D, Mishra, Ashwani, Yousuf, Mishra, Prabhakar, Lal, Punita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117020/
https://www.ncbi.nlm.nih.gov/pubmed/36722567
http://dx.doi.org/10.4103/ajps.ajps_152_21
_version_ 1785028544477265920
author Kumar, Basant
Yadav, Rajanikant
Upadhyaya, Vijai D
Mishra, Ashwani
Yousuf,
Mishra, Prabhakar
Lal, Punita
author_facet Kumar, Basant
Yadav, Rajanikant
Upadhyaya, Vijai D
Mishra, Ashwani
Yousuf,
Mishra, Prabhakar
Lal, Punita
author_sort Kumar, Basant
collection PubMed
description BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours from January 2014 to March 2020. Data analysed were pertaining to the age, sex, presentation, site, stage, diagnostic evaluation performed, management and follow-up results, etc., The final outcomes were assessed as complete response; partial response (PR); no response (NR) and progressive disease. International Neuroblastoma Risk Group staging was used and patients were categorised on the basis of age, site and stage of tumour. Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up and event for OS was death. RESULTS: Forty-seven patients were included with median age of 60 months (ranges of 2–180; mean = 61.87 ± 47.56). About 72.3% (n = 34) patients were males. Out of total, 6.4% (n = 3), 53.2% (n = 25) and 38.3% (n = 18) were in stage L1, L2 and M, respectively, whereas 2.1% (n = 1) patients were in stage MS. Surgery was performed in 25 (53.19%) patients, but gross total excision was achieved in 48.90% (n = 23) patients. Onlu 10.60% (n = 5) patients were referred, whereas 14.89% (n = 7) patients reported recurrences. Mean and median follow-up time of the patients was 24.64 ± 16.04 and 18 months (range: 3–60 months). Out of total, 53.2% (n = 25) and 29.8% (n = 14) patients had complete and PRs, respectively, whereas 17% (n = 8) patients had NR. Out of the total 47 patients, 8 (17%) achieved events (deaths), whereas the rest, 39 (83%) patients, were censored. Mean event-free OS time was 50.04 months. CONCLUSION: There was a significant difference in patient deaths in recurrence and non-recurred patients (4/7, 57.1% vs. 4/40/, 10%, P = 0.011). Survival time was significantly higher in patients with stages L1-L2 as compared to Stage 4. Stage and age were found predictors of survival.
format Online
Article
Text
id pubmed-10117020
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-101170202023-04-21 Neuroblastic Tumours in Children: Outcome from a Referral Centre in India Kumar, Basant Yadav, Rajanikant Upadhyaya, Vijai D Mishra, Ashwani Yousuf, Mishra, Prabhakar Lal, Punita Afr J Paediatr Surg Original Article BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours from January 2014 to March 2020. Data analysed were pertaining to the age, sex, presentation, site, stage, diagnostic evaluation performed, management and follow-up results, etc., The final outcomes were assessed as complete response; partial response (PR); no response (NR) and progressive disease. International Neuroblastoma Risk Group staging was used and patients were categorised on the basis of age, site and stage of tumour. Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up and event for OS was death. RESULTS: Forty-seven patients were included with median age of 60 months (ranges of 2–180; mean = 61.87 ± 47.56). About 72.3% (n = 34) patients were males. Out of total, 6.4% (n = 3), 53.2% (n = 25) and 38.3% (n = 18) were in stage L1, L2 and M, respectively, whereas 2.1% (n = 1) patients were in stage MS. Surgery was performed in 25 (53.19%) patients, but gross total excision was achieved in 48.90% (n = 23) patients. Onlu 10.60% (n = 5) patients were referred, whereas 14.89% (n = 7) patients reported recurrences. Mean and median follow-up time of the patients was 24.64 ± 16.04 and 18 months (range: 3–60 months). Out of total, 53.2% (n = 25) and 29.8% (n = 14) patients had complete and PRs, respectively, whereas 17% (n = 8) patients had NR. Out of the total 47 patients, 8 (17%) achieved events (deaths), whereas the rest, 39 (83%) patients, were censored. Mean event-free OS time was 50.04 months. CONCLUSION: There was a significant difference in patient deaths in recurrence and non-recurred patients (4/7, 57.1% vs. 4/40/, 10%, P = 0.011). Survival time was significantly higher in patients with stages L1-L2 as compared to Stage 4. Stage and age were found predictors of survival. Wolters Kluwer - Medknow 2023 2023-01-31 /pmc/articles/PMC10117020/ /pubmed/36722567 http://dx.doi.org/10.4103/ajps.ajps_152_21 Text en Copyright: © 2023 African Journal of Paediatric Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kumar, Basant
Yadav, Rajanikant
Upadhyaya, Vijai D
Mishra, Ashwani
Yousuf,
Mishra, Prabhakar
Lal, Punita
Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title_full Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title_fullStr Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title_full_unstemmed Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title_short Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
title_sort neuroblastic tumours in children: outcome from a referral centre in india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117020/
https://www.ncbi.nlm.nih.gov/pubmed/36722567
http://dx.doi.org/10.4103/ajps.ajps_152_21
work_keys_str_mv AT kumarbasant neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT yadavrajanikant neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT upadhyayavijaid neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT mishraashwani neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT yousuf neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT mishraprabhakar neuroblastictumoursinchildrenoutcomefromareferralcentreinindia
AT lalpunita neuroblastictumoursinchildrenoutcomefromareferralcentreinindia